Meconium aspiration syndrome (MAS) is a common cause of lung disease in neonates. Meconium staining of amniotic fluid occurs in around 10% of all deliveries at term. Asphyxia before birth stimulates intestinal peristalsis and relaxation of the anal sphincter, and in more severe cases, gasping in utero, leading to meconium aspiration. Respiration after birth draws meconium firstly into the major airways and subsequently into the smaller airways, where it may cause obstruction, atelectasis, air trapping, and pneumothorax. Meconium can also cause a chemical pneumonitis and inactivation of surfactant, further impairing gas exchange and potentiating barotrauma. Infants with severe MAS rapidly develop pulmonary hypertension requiring mechanical ventilation.

The natural history of pulmonary hypertension is, in most cases, spontaneous recovery with time. The institution of ECMO therefore provides global tissue oxygenation while allowing pulmonary vasculature and lung parenchyma time to recover from the antecedent insults.

ECMO in the treatment of MAS

The use of ECMO in the treatment of MAS was first reported by Bartlett et al in 1977, who used ECMO to treat eight moribund neonates. Three of these infants survived, as compared with a 90% mortality in a “conventionally” treated group. The use of venoarterial (V-A) ECMO became increasingly popular throughout the United States during the 1980s, with consistently encouraging results for neonates treated with severe MAS. The criteria for instituting ECMO support were also refined over this time, and an oxygenation index of greater than 40 was suggested as a referral criterion. The oxygenation index is calculated as follows:

\[
\text{Oxygenation index} = \frac{\text{Paw} \times \text{FiO}_2}{\text{PaO}_2} \times 100
\]

where Paw = mean airway pressure, \( \text{FiO}_2 \) = inspired oxygen fraction, and \( \text{PaO}_2 \) = arterial oxygen tension (mm Hg).

Thus by the early 1990s, data from the extracorporeal life support organisation and three small randomised trials in the United States strongly supported the important
role of ECMO in the management of neonatal respiratory failure. However, it was only after the publication of the UK collaborative neonatal ECMO trial\(^1\) that ECMO became a relatively accepted method of support for neonates with MAS in this country. The results of this trial, which again used an oxygenation index of 40 as a referral criterion, concluded that, for every four infants receiving ECMO for MAS, there was one extra survivor. Furthermore, although infants with MAS tend to do relatively less well when treated conventionally than other term neonates with respiratory failure, the converse is true when ECMO support is used. The survival figures for neonates with MAS who receive ECMO are extremely encouraging, and UK ECMO centres currently quote survival figures of around 90% for neonates in whom the primary indication is pulmonary hypertension, without associated severe lung injury attributable to prolonged aggressive ventilation.

**ECMO techniques**

Two modes of ECMO can be used to support neonates with MAS. Most ECMO centres initially used V-A support, in which the right common carotid artery and internal jugular veins were cannulated, thus providing cardiac and respiratory support. More recently, however, venovenous (V-V) ECMO has emerged as the method of choice for neonates with hypoxic respiratory failure and without significant haemodynamic instability.\(^1\) In V-V ECMO, a double lumen venous cannula is inserted into the right internal jugular vein with its tip in the right atrium; one lumen carries “venous” blood from the patient to the oxygenator, and the “arterial” lumen returns oxygenated blood to the heart.\(^1\) Most neonates with MAS now receive V-V ECMO.

Inotropes are not a contraindication to V-V ECMO. Modest doses of inotropes are often required to balance the detrimental cardiovascular effects of high airway pressures. Furthermore, hypoxia itself is a potent pulmonary vasoconstrictor, and thus right ventricular performance is often significantly diminished as a result of increased afterload. Finally, global hypoxia takes its toll on the myocardium, the oxygen demands of which will by far outweigh its supply, and so myocardial performance can be impaired as a result.

The potential advantages of V-V over V-A ECMO are the reduced risk of intracranial haemorrhage and the theoretical advantage of preserving the intact carotid circulation. Cannulation of the artery, as well as predisposing to arterial intracranial bleeds while on ECMO, will inevitably lead to disruption of flow after decannulation, either as a result of ligation of the vessel or because of the presence of a substrate for turbulence or aneurysm formation if the vessel is repaired.\(^1\)\(^-\)\(^10\)

**Duration of ECMO support**

ECMO support is usually required for between 100 and 120 hours\(^1\)\(^1\) in MAS, the shortest duration for any neonatal diagnosis. However, this duration will inevitably be significantly increased if high pressure/volume ventilation has led to air leaks before cannulation. While on ECMO, the infant receives “resting ventilation” with slow background ventilation with a moderate level of PEEP to maintain lung expansion (rate 10/min, pressures 20/10). Serial radiographs often show a complete “white out” during the first two to three days (fig 1), with subsequent reappearance of air bronchograms and resolution of the changes as the lungs recover. Lung compliance can be estimated both manually and mechanically while the infant is on ECMO. Unless precipitous decannulation is required for other reasons—for example, large intracranial bleed—the infant is weaned from support when only minimal ventilatory support is needed to provide adequate lung expansion, oxygenation, and gas exchange. At this stage, there is usually radiological evidence of significant lung recovery.

**Long term outcome in MAS treated with ECMO**

The worldwide survival rate for over 5000 neonates with MAS receiving ECMO support is 94%,\(^2\)\(^1\) which is in line with the UK experience when an oxygenation index of 40 is used as the referral criterion. This is the highest survival rate for any neonatal condition suitable for ECMO. There is also evidence to suggest reduced mechanical and patient related complication rates compared with other subgroups.\(^2\)\(^2\)\(^-\)\(^2\)\(^4\)

In terms of long term morbidity, survivors of ECMO do not appear to have any increased rate of disability or neurological damage than other severely hypoxic, conventionally treated neonates with MAS, despite a greater proportion surviving.\(^2\)\(^\)\(^1\)\(^-\)\(^4\)

**Alternatives to ECMO in severe MAS**

Other forms of treatment have been suggested for neonates with MAS, including surfactant,\(^2\)\(^5\)\(^-\)\(^7\) inhaled nitric oxide,\(^2\)\(^8\)\(^-\)\(^9\) and even liquid ventilation.\(^2\)\(^0\) However, despite some improvements in oxygenation even within these trials, there were still neonates who required ECMO support. Indeed these various forms of support and therapy are not necessarily mutually exclusive. For instance, surfactant has also been used in neonates supported with ECMO, resulting in improved pulmonary mechanics, reduced time on ECMO, and reduced disease complications.\(^3\)\(^1\)

---

**Figure 1 Chest radiograph of infant with severe meconium aspiration syndrome showing typical “white out” appearance 24 hours after institution of venoarterial extracorporeal membrane oxygenation support. The arterial cannula (A) has been inserted into the right common carotid artery, with its tip in the aortic arch; the venous cannula (B) has been inserted into the right internal jugular vein and its tip (C) lies in the right atrium.**

---

**Key messages**

Infants with severe MAS are relatively “ideal” candidates for ECMO in that:

- almost all are > 34 weeks gestation and weigh > 2 kg (cut off for ECMO)
- they have a potentially reversible respiratory problem
- associated pulmonary hypertension, although severe, is almost always reversible
- these infants need the “lung rest” that ECMO provides
- ECMO is an effective form of treatment for infants meeting the criteria
- as a subgroup, patients with MAS have a very favourable outcome
Conclusions
Despite the weight of evidence pointing to the efficacy of ECMO in supporting neonates with severe MAS, without causing excess morbidity, some infants with an oxygen index greater than 40 are still referred late for ECMO, after high pressure ventilation has already caused major lung damage, or after other organs—in particular the brain—have been subjected to prolonged hypoxia.

At a time when so little of our neonatal, or indeed paediatric, intensive care practice can be truly described as evidence based, neonatal intensivists will welcome the opportunity to clinically apply the compelling evidence that supports the role of ECMO in the treatment of MAS. This means early recognition of the potential need for ECMO in affected infants, guided by oxygenation index, and early discussion of these cases with designated neonatal ECMO centres. Thus the use of ECMO in severe MAS should be regarded not as a “last resort” when other treatment has failed, but more as an extension of conventional treatment.

PJ DAVIS
Heartlink ECMO Centre, Glenfield Hospital, Leicester, UK
L S SHEKERDEMIAN
Cardiac Intensive Care Unit, Great Ormond Street Hospital, London, UK

12 Bifano EM, Hakanson DO, Hingre RV, Gross SJ. Prospective randomized controlled trial of conventional treatment or transport for ECMO in infants with persistent pulmonary hypertension (PPHN) [abstract]. Pediatr Res 1992;34:196A.

STAMPS IN NEONATOLOGY

Hospitals and clinics

Hospitals feature occasionally on stamps but maternity hospitals much less frequently. The maternity hospital in Dakar, Senegal is found on seven stamps from the former French colonies issue in 1942 for the Colonial Child Welfare Fund. The same design is shared—only the country’s name altered between stamps. In this instance the stamp from the Ivory Coast is shown.

M K DAVIES
A J MAYNE